EcoR1 Capital as of Dec. 31, 2018
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 53 positions in its portfolio as reported in the December 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Argenx Se (ARGX) | 7.9 | $79M | 825k | 96.07 | |
| Kura Oncology (KURA) | 7.4 | $74M | 5.3M | 14.04 | |
| Fibrogen (FGEN) | 7.1 | $71M | 1.5M | 46.28 | |
| Ironwood Pharmaceuticals (IRWD) | 5.6 | $56M | 5.4M | 10.36 | |
| Assembly Biosciences | 5.4 | $54M | 2.4M | 22.62 | |
| Spark Therapeutics | 4.5 | $45M | 1.1M | 39.14 | |
| Ascendis Pharma A S (ASND) | 4.3 | $43M | 680k | 62.65 | |
| Ionis Pharmaceuticals (IONS) | 3.9 | $39M | 725k | 54.06 | |
| Fibrogen | 3.9 | $39M | 841k | 46.28 | |
| Xencor (XNCR) | 3.6 | $36M | 989k | 36.16 | |
| Dicerna Pharmaceuticals | 3.5 | $36M | 3.3M | 10.69 | |
| Scholar Rock Hldg Corp (SRRK) | 3.4 | $34M | 1.5M | 22.97 | |
| Mirati Therapeutics | 2.8 | $28M | 647k | 42.42 | |
| Kezar Life Sciences (KZR) | 2.5 | $25M | 1.1M | 23.60 | |
| Solid Biosciences | 2.3 | $23M | 867k | 26.80 | |
| Ascendis Pharma A S put | 2.3 | $23M | 360k | 62.65 | |
| Akcea Therapeutics Inc equities | 1.9 | $19M | 640k | 30.14 | |
| Gilead Sciences Inc option | 1.8 | $18M | 285k | 62.55 | |
| Eiger Biopharmaceuticals | 1.6 | $16M | 1.6M | 10.16 | |
| Unity Biotechnology | 1.6 | $16M | 967k | 16.26 | |
| Ascendis Pharma A S call | 1.6 | $16M | 250k | 62.65 | |
| Sangamo Biosciences (SGMO) | 1.4 | $14M | 1.2M | 11.48 | |
| Zai Lab (ZLAB) | 1.3 | $13M | 569k | 23.22 | |
| Arcus Biosciences Incorporated (RCUS) | 1.3 | $13M | 1.2M | 10.77 | |
| Arbutus Biopharma (ABUS) | 1.3 | $13M | 3.3M | 3.83 | |
| Celgene Corp option | 1.2 | $13M | 195k | 64.09 | |
| Ironwood Pharmaceuticals Inc cl a | 1.2 | $12M | 1.2M | 10.36 | |
| Myokardia | 1.1 | $12M | 234k | 48.86 | |
| Rhythm Pharmaceuticals (RYTM) | 1.1 | $11M | 401k | 26.88 | |
| Nektar Therapeutics | 1.0 | $10M | 317k | 32.87 | |
| Wave Life Sciences (WVE) | 1.0 | $9.8M | 234k | 42.04 | |
| Surface Oncology | 1.0 | $9.6M | 2.3M | 4.24 | |
| Rubius Therapeutics | 0.9 | $9.5M | 592k | 16.08 | |
| Array BioPharma | 0.9 | $9.2M | 644k | 14.25 | |
| Prothena (PRTA) | 0.9 | $8.6M | 838k | 10.30 | |
| Magenta Therapeutics | 0.8 | $7.9M | 1.4M | 5.70 | |
| Immune Design | 0.7 | $7.3M | 5.6M | 1.30 | |
| Rocket Pharmaceuticals (RCKT) | 0.7 | $6.7M | 450k | 14.82 | |
| Crispr Therapeutics (CRSP) | 0.6 | $6.0M | 209k | 28.57 | |
| Aquinox Pharmaceuticals | 0.5 | $4.9M | 2.3M | 2.16 | |
| Portola Pharmaceuticals | 0.5 | $4.8M | 248k | 19.52 | |
| Aclaris Therapeutics (ACRS) | 0.5 | $4.5M | 614k | 7.39 | |
| Five Prime Therapeutics | 0.3 | $3.0M | 327k | 9.30 | |
| Corcept Therapeutics Incorporated (CORT) | 0.2 | $2.2M | 166k | 13.36 | |
| Curis | 0.2 | $2.1M | 3.0M | 0.69 | |
| Dynavax Technologies (DVAX) | 0.1 | $1.3M | 140k | 9.15 | |
| Chiasma | 0.1 | $1.2M | 380k | 3.11 | |
| Corvus Pharmaceuticals (CRVS) | 0.1 | $1.1M | 295k | 3.67 | |
| Onconova Therapeutics | 0.1 | $894k | 423k | 2.11 | |
| Arvinas Ord (ARVN) | 0.1 | $643k | 50k | 12.86 | |
| Affimed Therapeutics B V | 0.1 | $492k | 158k | 3.11 | |
| Constellation Pharmceticls I | 0.0 | $318k | 79k | 4.02 | |
| Proqr Thrapeutics N V shs euro (PRQR) | 0.0 | $174k | 11k | 15.79 |
